

cannot guarantee that we will be able to do so.

CALIFORNIA

Monterey County

Aeneas Sardine Packing Company Cannery,
300 Cannery Row, Monterey, 15000739

COLORADO

Routt County

Hayden Co-Operative Elevator Company, 198
E. Lincoln Ave., Hayden, 15000740

DISTRICT OF COLUMBIA

District of Columbia

Capitol Hill Historic District (Boundary Increase II), Squares 752, 753, 777, 788 bounded by 2nd, 4th & F Sts. NE., Washington, 15000741

Davis, Colonel William Robert, House, 3020 Albemarle St. NW., Washington, 15000742

Young, Browne, Phelps and Springarn Educational Campus Historic District, (Public School Buildings of Washington, DC MPS) 2500 Benning Rd. NE., 704, 820, & 850 26th St. NE., Washington, 15000743

GEORGIA

Stephens County

Toccoa Downtown Historic District (Boundary Increase), 118 W. Doyle St., Toccoa, 15000744

IOWA

Carroll County

Manning Commercial Historic District, (Iowa's Main Street Commercial Architecture MPS) 217-411, 413-507, 302-326 Main, 717-723 3rd, 303 Center & 825 5th Sts., Manning, 15000745

Henry County

Benjamin Chapel and Richwoods Cemetery, 1936 Franklin Ave., Trenton, 15000746

Boyle, Hugh and Matilda, House and Cemetery Historic District, 3225 Lexington Ave., Lowell, 15000747

Edwards, Joseph A. and Lydia A., House, 1735 Salem Rd., Salem, 15000748

Garretson, Owen A. and Emma J., House, 1878 335th St., Salem, 15000750

Linn County

Cedar Rapids 2nd Avenue SE. Automobile Row Historic District, Roughly 2nd to 3rd Aves., SE., from 6th to 8th Sts., SE., Cedar Rapids, 15000749

Monroe Elementary School Historic District, 3200 Pioneer Ave., SE., Cedar Rapids, 15000751

Montgomery County

Ellis, William and Amanda J., Farmstead Historic District, 1134 I Ave., Elliott, 15000752

NEW YORK

Essex County

Helen Hill Historic District, Prescott Place, Helen & Front Sts., Sheppard, Franklin & Clinton Aves., Saranac Lake, 15000754

OHIO

Hamilton County

William Howard Taft National Historic Site (Boundary Increase and Additional Documentation, 2038 Auburn Ave., Cincinnati, 15000753

A request to move has been made for the following resource:

INDIANA

Clay County

Indiana State Highway Bridge 46-11-1316, IN 46 over Eel R., Bowling Green, 00000211

In the interest of preservation a three day comment period has been requested for the following resource:

WISCONSIN

Ozaukee County

SENATOR (steam screw) Shipwreck, (Great Lakes Shipwreck Sites of Wisconsin MPS) Address Restricted, Port Washington, 15000738

Authority: 60.13 of 36 CFR part 60

Dated: September 16, 2015.

Roger Reed,

Acting Chief, National Register of Historic Places/National Historic Landmarks Program.

[FR Doc. 2015-25375 Filed 10-5-15; 8:45 am]

BILLING CODE 4312-51-P

JOINT BOARD FOR THE ENROLLMENT OF ACTUARIES

Meeting of the Advisory Committee; Meeting

AGENCY: Joint Board for the Enrollment of Actuaries

ACTION: Notice of Federal Advisory Committee meeting.

SUMMARY: The Executive Director of the Joint Board for the Enrollment of Actuaries gives notice of a closed teleconference meeting of the Advisory Committee on Actuarial Examinations.

DATES: The meeting will be held on October 30, 2015, from 8:30 a.m. to 5:00 p.m.

FOR FURTHER INFORMATION CONTACT: Patrick W. McDonough, Executive Director of the Joint Board for the Enrollment of Actuaries, 703-414-2173.

SUPPLEMENTARY INFORMATION:

Notice is hereby given that the Advisory Committee on Actuarial Examinations will hold a teleconference meeting on October 30, 2015, from 8:30 a.m. to 5:00 p.m. The meeting will be closed to the public.

The purpose of the meeting is to discuss topics and questions that may be recommended for inclusion on future Joint Board examinations in actuarial

mathematics, pension law and methodology referred to in 29 U.S.C. 1242(a)(1)(B).

A determination has been made as required by section 10(d) of the Federal Advisory Committee Act, 5 U.S.C. App., that the subject of the meeting falls within the exception to the open meeting requirement set forth in Title 5 U.S.C. 552b(c)(9)(B), and that the public interest requires that such meeting be closed to public participation.

Dated: September 21, 2015.

Patrick W. McDonough,

Executive Director, Joint Board for the Enrollment of Actuaries.

[FR Doc. 2015-25342 Filed 10-5-15; 8:45 am]

BILLING CODE 4830-01-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-420F]

Established Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2016

AGENCY: Drug Enforcement Administration, Department of Justice.

ACTION: Final order.

SUMMARY: This final order establishes the initial 2016 aggregate production quotas for controlled substances in schedules I and II of the Controlled Substances Act (CSA) and the assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine.

DATES: Effective October 6, 2015.

FOR FURTHER INFORMATION CONTACT: John R. Scherbenske, Office of Diversion Control, Drug Enforcement Administration, 8701 Morrisette Drive, Springfield, VA 22152, Telephone: (202) 598-6812.

SUPPLEMENTARY INFORMATION:

Legal Authority

The Drug Enforcement Administration (DEA) implements and enforces titles II and III of the Comprehensive Drug Abuse Prevention and Control Act of 1970, as amended. Titles II and III are referred to as the "Controlled Substances Act" and the "Controlled Substances Import and Export Act," respectively, and are collectively referred to as the "Controlled Substances Act" or the "CSA" for the purpose of this action. 21

U.S.C. 801–971. The DEA publishes the implementing regulations for these statutes in title 21 of the Code of Federal Regulations (CFR), chapter II. The CSA and its implementing regulations are designed to prevent, detect, and eliminate the diversion of controlled substances and listed chemicals into the illicit market while ensuring an adequate supply is available for the legitimate medical, scientific, research, and industrial needs of the United States. Controlled substances have the potential for abuse and dependence and are controlled to protect the public health and safety.

Section 306 of the Controlled Substances Act (CSA), 21 U.S.C. 826, requires the Attorney General to determine the total quantity and establish production quotas for each basic class of controlled substance in schedules I and II and for ephedrine, pseudoephedrine, and phenylpropanolamine to be manufactured each calendar year to provide for the estimated medical, scientific, research, and industrial needs of the United States, for lawful export requirements, and for the establishment and maintenance of reserve stocks. This responsibility has been delegated to the Administrator of the DEA through 28 CFR 0.100(b).

Background

The 2016 aggregate production quotas and assessment of annual needs represent those quantities of schedule I and II controlled substances and the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine that may be manufactured in the United States in 2016 to provide for the estimated medical, scientific, research, and industrial needs of the United States, lawful export requirements, and the establishment and maintenance of reserve stocks. These quotas include imports of ephedrine, pseudoephedrine, and phenylpropanolamine but do not include imports of controlled substances for use in industrial processes.

On July 17, 2015, a notice titled, “Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Proposed Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2016” was published in the **Federal Register**. 80 FR 42540. This notice proposed the 2016 aggregate production quotas for each basic class of controlled substance listed in schedules I and II and the 2016 assessment of annual needs for the list I chemicals ephedrine,

pseudoephedrine, and phenylpropanolamine. All interested persons were invited to comment on or object to the proposed aggregate production quotas and the proposed assessment of annual needs on or before August 17, 2015.

Comments Received

Twenty comments were received from four DEA-registered manufacturers within the published comment period regarding 17 different schedule I and II controlled substances. The DEA did not receive any comments regarding the proposed assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine. Commenters stated that the proposed aggregate production quotas for [1-(5-fluoropentyl)-1*H*-indazol-3-yl](naphthalen-1-yl)methanone (THJ-2201), amphetamine (for sale), codeine (for sale), gamma hydroxybutric acid, levorphanol, marihuana, methylphenidate, *N*-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1*H*-indazole-3-carboxamide (ADB-PINACA), *N*-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1*H*-indazole-3-carboxamide (AB-FUBINACA), *N*-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1*H*-indazole-3-carboxamide (AB-CHMINACA), *N*-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1*H*-indazole-3-carboxamide (AB-PINACA), *N*-(1-phenethylpiperidin-4-yl)-*N*-phenylacetamide (acetyl fentanyl), nabilone, oxymorphone (for conversion), oxymorphone (for sale), Quinolin-8-yl 1-(5-fluoropentyl)-1*H*-indole-3-carboxylate (5-Flouro-PB-22), and Quinolin-8-yl 1-pentyl-1*H*-indole-3-carboxylate (PB-22) were insufficient to provide for the estimated medical, scientific, research, and industrial needs of the United States, export requirements, and the establishment and maintenance of reserve stocks.

Determination of 2016 Aggregate Production Quotas and Assessment of Annual Needs

In determining the 2016 aggregate production quotas and assessment of annual needs, the DEA has taken into consideration the above comments along with the factors set forth at 21 CFR 1303.11 and 21 CFR 1315.11, in accordance with 21 U.S.C. 826(a), and other relevant factors, including the 2015 manufacturing quotas, current 2015 sales and inventories, anticipated 2016 export requirements, industrial use, additional applications for 2016 quotas, as well as information on research and product development

requirements. Based on this information, the DEA has determined that adjustments to the proposed aggregate production quotas for codeine (for sale), hydromorphone, marihuana, methylphenidate, and *N*-(1-phenethylpiperidin-4-yl)-*N*-phenylacetamide (acetyl fentanyl) are warranted. This final order reflects those adjustments.

Regarding [1-(5-fluoropentyl)-1*H*-indazol-3-yl](naphthalen-1-yl)methanone (THJ-2201), amphetamine (for sale), gamma hydroxybutric acid, levorphanol, *N*-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1*H*-indazole-3-carboxamide (ADB-PINACA), *N*-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1*H*-indazole-3-carboxamide (AB-FUBINACA), *N*-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1*H*-indazole-3-carboxamide (AB-CHMINACA), *N*-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1*H*-indazole-3-carboxamide (AB-PINACA), nabilone, oxymorphone (for conversion), oxymorphone (for sale), Quinolin-8-yl 1-(5-fluoropentyl)-1*H*-indole-3-carboxylate (5-Flouro-PB-22), and Quinolin-8-yl 1-pentyl-1*H*-indole-3-carboxylate (PB-22), the DEA has determined that the proposed aggregate production quotas are sufficient to provide for the 2016 estimated medical, scientific, research, and industrial needs of the United States, export requirements, and the establishment and maintenance of reserve stocks. This final order establishes these aggregate production quotas at the same amounts as proposed.

As described in the previously published notice proposing the 2016 aggregate production quotas and assessment of annual needs, the DEA has specifically considered that inventory allowances granted to individual manufacturers may not always result in the availability of sufficient quantities to maintain an adequate reserve stock pursuant to 21 U.S.C. 826(a), as intended. See 21 CFR 1303.24. This would be concerning if a natural disaster or other unforeseen event resulted in substantial disruption to the amount of controlled substances available to provide for legitimate public need. As such, the DEA has included in all established schedule II aggregate production quotas, and certain schedule I aggregate production quotas, an additional 25% of the estimated medical, scientific, and research needs as part of the amount necessary to ensure the establishment and maintenance of reserve stocks. The established aggregate production quotas will reflect these included amounts. This action will not affect the ability of

manufacturers to maintain inventory allowances as specified by regulation. The DEA expects that maintaining this reserve in certain established aggregate production quotas will mitigate adverse public effects if an unforeseen event results in the substantial disruption to the amount of controlled substances

available to provide for legitimate public need, as determined by the DEA. The DEA does not anticipate utilizing the reserve in the absence of these circumstances.

In accordance with 21 U.S.C. 826, 21 CFR 1303.11, and 21 CFR 1315.11, the Administrator hereby establishes the

2016 aggregate production quotas for the following schedule I and II controlled substances and the 2016 assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, expressed in grams of anhydrous acid or base, as follows:

Basic class	Established 2016 quotas (g)
Schedule I	
(1-Pentyl-1 <i>H</i> -indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144)	25
[1-(5-fluoropentyl)-1 <i>H</i> -indazol-3-yl](naphthalen-1-yl)methanone (THJ-2201)	15
[1-(5-Fluoro-pentyl)-1 <i>H</i> -indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (XLR11)	25
1-(1,3-Benzodioxol-5-yl)-2-(methylamino)butan-1-one (butylone)	25
1-(1,3-Benzodioxol-5-yl)-2-(methylamino)pentan-1-one (pentylone)	25
1-(1-Phenylcyclohexyl)pyrrolidine	10
1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201)	45
1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694)	45
1-[1-(2-Thienyl)cyclohexyl]piperidine	15
1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200)	45
1-Butyl-3-(1-naphthoyl)indole (JWH-073)	45
1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (SR-18 and RCS-8)	45
1-Hexyl-3-(1-naphthoyl)indole (JWH-019)	45
1-Methyl-4-phenyl-4-propionoxypiperidine	2
1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM678)	45
1-Pentyl-3-(2-chlorophenylacetyl)indole (JWH-203)	45
1-Pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250)	45
1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398)	45
1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122)	45
1-Pentyl-3-[(4-methoxy)-benzoyl]indole (SR-19, RCS-4)	45
1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081)	45
2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E)	30
2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D)	30
2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N)	30
2-(2,5-Dimethoxy-4- <i>n</i> -propylphenyl)ethanamine (2C-P)	30
2-(2,5-Dimethoxyphenyl)ethanamine (2C-H)	30
2-(4-Bromo-2,5-dimethoxyphenyl)- <i>N</i> -(2-methoxybenzyl)ethanamine (25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36)	25
2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C)	30
2-(4-Chloro-2,5-dimethoxyphenyl)- <i>N</i> -(2-methoxybenzyl)ethanamine (25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82)	25
2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I)	30
2-(4-Iodo-2,5-dimethoxyphenyl)- <i>N</i> -(2-methoxybenzyl)ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5)	15
2-(Methylamino)-1-phenylpentan-1-one (pentedrone)	25
2,5-Dimethoxy-4-ethylamphetamine (DOET)	25
2,5-Dimethoxy-4- <i>n</i> -propylthiophenethylamine	25
2,5-Dimethoxyamphetamine	25
2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2)	30
2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4)	30
3,4,5-Trimethoxyamphetamine	25
3,4-Methylenedioxyamphetamine (MDA)	55
3,4-Methylenedioxymethamphetamine (MDMA)	50
3,4-Methylenedioxy- <i>N</i> -ethylamphetamine (MDEA)	40
3,4-Methylenedioxy- <i>N</i> -methylcathinone (methylone)	50
3,4-Methylenedioxypropylvalerone (MDPV)	35
3-Fluoro- <i>N</i> -methylcathinone (3-FMC)	25
3-Methylfentanyl	2
3-Methylthiofentanyl	2
4-Bromo-2,5-dimethoxyamphetamine (DOB)	25
4-Bromo-2,5-dimethoxyphenethylamine (2-CB)	25
4-Fluoro- <i>N</i> -methylcathinone (4-FMC)	25
4-Methoxyamphetamine	150
4-Methyl-2,5-dimethoxyamphetamine (DOM)	25
4-Methylaminorex	25
4-Methyl- <i>N</i> -ethylcathinone (4-MEC)	25
4-Methyl- <i>N</i> -methylcathinone (mephedrone)	45
4-Methyl- α -pyrrolidinopropiophenone (4-MePPP)	25
5-(1,1-Dimethylheptyl)-2-[(1 <i>R</i> ,3 <i>S</i>)-3-hydroxycyclohexyl]-phenol	68
5-(1,1-Dimethyloctyl)-2-[(1 <i>R</i> ,3 <i>S</i>)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP-47,497 C8-homolog)	53
5-Methoxy-3,4-methylenedioxyamphetamine	25
5-Methoxy- <i>N,N</i> -diisopropyltryptamine	25
5-Methoxy- <i>N,N</i> -dimethyltryptamine	25
Acetyl- α -methylfentanyl	2

Basic class	Established 2016 quotas (g)
Acetyldihydrocodeine	2
Acetylmethadol	2
Allylprodine	2
Alphacetylmethadol	2
<i>alpha</i> -Ethyltryptamine	25
Alphameprodine	2
Alphamethadol	2
<i>alpha</i> -Methylfentanyl	2
<i>alpha</i> -Methylthiofentanyl	2
<i>alpha</i> -Methyltryptamine (AMT)	25
<i>alpha</i> -Pyrrolidinobutiophenone (α -PBP)	25
<i>alpha</i> -Pyrrolidinopentiophenone (α -PVP)	25
Aminorex	25
Benzylmorphine	2
Betacetylmethadol	2
<i>beta</i> -Hydroxy-3-methylfentanyl	2
<i>beta</i> -Hydroxyfentanyl	2
Betameprodine	2
Betamethadol	4
Betaprodine	2
Bufotenine	3
Cathinone	70
Codeine methylbromide	5
Codeine- <i>N</i> -oxide	305
Desomorphine	25
Diethyltryptamine	25
Difenoxin	11,000
Dihydromorphine	3,000,000
Dimethyltryptamine	35
Dipipanone	5
Fenethylamine	5
<i>gamma</i> -Hydroxybutyric acid	70,250,000
Heroin	50
Hydromorphinol	2
Hydroxypethidine	2
Ibogaine	5
Lysergic acid diethylamide (LSD)	40
Marihuana	658,000
Mescaline	25
Methaqualone	10
Methcathinone	25
Methyldesorphine	5
Methyldihydromorphine	2
Morphine methylbromide	5
Morphine methylsulfonate	5
Morphine- <i>N</i> -oxide	350
<i>N</i> -(1-Adamantyl)-1-pentyl-1 <i>H</i> -indazole-3-carboxamide (AKB48)	25
<i>N</i> -(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1 <i>H</i> -indazole-3-carboxamide (ADB-PINACA)	50
<i>N</i> -(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1 <i>H</i> -indazole-3-carboxamide (AB-FUBINACA)	50
<i>N</i> -(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1 <i>H</i> -indazole-3-carboxamide (AB-CHMINACA)	15
<i>N</i> -(1-Amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1 <i>H</i> -indazole-3-carboxamide (AB-PINACA)	15
<i>N</i> -(1-phenethylpiperidin-4-yl)- <i>N</i> -phenylacetamide (acetyl fentanyl)	100
<i>N,N</i> -Dimethylamphetamine	25
Naphthylpyrovalerone (naphyrone)	25
<i>N</i> -Benzylpiperazine	25
<i>N</i> -Ethyl-1-phenylcyclohexylamine	5
<i>N</i> -Ethylamphetamine	24
<i>N</i> -Hydroxy-3,4-methylenedioxyamphetamine	24
Noracetylmethadol	2
Norlevorphanol	52
Normethadone	2
Normorphine	40
Para-fluorofentanyl	5
Parahexyl	5
Phenomorphan	2
Pholcodine	5
Psilocybin	30
Psilocyn	50
Quinolin-8-yl 1-(5-fluoropentyl)-1 <i>H</i> -indole-3-carboxylate (5-fluoro-PB-22; 5F-PB-22)	50
Quinolin-8-yl 1-pentyl-1 <i>H</i> -indole-3-carboxylate (PB-22; QUPIC)	50
Tetrahydrocannabinols	511,250
Thiofentanyl	2
Tilidine	25

Basic class	Established 2016 quotas (g)
Trimeperidine	2
Schedule II	
1-Phenylcyclohexylamine	5
1-Piperidinocyclohexanecarbonitrile	5
4-Anilino- <i>N</i> -phenethyl-4-piperidine (ANPP)	2,950,000
Alfentanil	17,750
Alphaprodine	3
Amobarbital	25,125
Amphetamine (for conversion)	15,000,000
Amphetamine (for sale)	39,705,000
Carfentanil	19
Cocaine	200,000
Codeine (for conversion)	50,000,000
Codeine (for sale)	63,900,000
Dextropropoxyphene	45
Dihydrocodeine	226,375
Dihydroetorphine	3
Diphenoxylate (for conversion)	31,250
Diphenoxylate (for sale)	1,337,500
Ecgonine	125,000
Ethylmorphine	3
Etorphine hydrochloride	3
Fentanyl	2,300,000
Glutethimide	3
Hydrocodone (for conversion)	235,000
Hydrocodone (for sale)	88,500,000
Hydromorphone	8,250,000
Isomethadone	5
Levo-alphaacetylmethadol (LAAM)	4
Levomethorphan	30
Levorphanol	7,125
Lisdexamfetamine	29,750,000
Meperidine	5,450,000
Meperidine Intermediate-A	6
Meperidine Intermediate-B	11
Meperidine Intermediate-C	6
Metazocine	19
Methadone (for sale)	31,875,000
Methadone Intermediate	34,375,000
Methamphetamine	2,061,375
[1,250,000 grams of <i>levo</i> -desoxyephedrine for use in a non-controlled, non-prescription product; 750,000 grams for methamphetamine mostly for conversion to a schedule III product; and 61,375 grams for methamphetamine (for sale)]	
Methylphenidate	96,750,000
Morphine (for conversion)	91,250,000
Morphine (for sale)	62,500,000
Nabilone	18,750
Noroxymorphone (for conversion)	17,500,000
Noroxymorphone (for sale)	1,475,000
Opium (powder)	112,500
Opium (tincture)	687,500
Oripavine	30,000,000
Oxycodone (for conversion)	6,250,000
Oxycodone (for sale)	139,150,000
Oxymorphone (for conversion)	29,000,000
Oxymorphone (for sale)	7,750,000
Pentobarbital	38,125,000
Phenazocine	6
Phencyclidine	50
Phenmetrazine	3
Phenylacetone	50
Racemethorphan	3
Racemorphan	3
Remifentanyl	3,750
Secobarbital	215,003
Sufentanil	6,255
Tapentadol	25,500,000
Thebaine	125,000,000

Basic class	Established 2016 quotas (g)
List I Chemicals	
Ephedrine (for conversion)	100,000
Ephedrine (for sale)	4,000,000
Phenylpropanolamine (for conversion)	22,400,000
Phenylpropanolamine (for sale)	8,500,000
Pseudoephedrine (for conversion)	7,000
Pseudoephedrine (for sale)	224,500,000

The Administrator also establishes aggregate production quotas for all other schedule I and II controlled substances included in 21 CFR 1308.11 and 1308.12 at zero. In accordance with 21 CFR 1303.13 and 21 CFR 1315.13, upon consideration of the relevant factors, the Administrator may adjust the 2016 aggregate production quotas and assessment of annual needs as needed.

Dated: September 30, 2015.

Chuck Rosenberg,

Acting Administrator.

[FR Doc. 2015-25373 Filed 10-5-15; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Foreign Claims Settlement Commission

[F.C.S.C. Meeting and Hearing Notice No. 09-15]

Sunshine Act Meeting

The Foreign Claims Settlement Commission, pursuant to its regulations (45 CFR 503.25) and the Government in the Sunshine Act (5 U.S.C. 552b), hereby gives notice in regard to the scheduling of open meetings as follows:

Thursday, October 15, 2015: 10 a.m.— Issuance of Proposed Decisions in claims against Libya.

Status: Open

All meetings are held at the Foreign Claims Settlement Commission, 600 E Street NW., Washington, DC. Requests for information, or advance notices of intention to observe an open meeting, may be directed to: Patricia M. Hall, Foreign Claims Settlement Commission, 600 E Street NW., Suite 6002, Washington, DC 20579. Telephone: (202) 616-6975.

Brian M. Simkin,

Chief Counsel.

[FR Doc. 2015-25500 Filed 10-2-15; 4:15 pm]

BILLING CODE 4410-BA-P

DEPARTMENT OF JUSTICE

Notice of Lodging of Proposed Consent Decree Under the Clean Air Act

On September 29, 2015, the Department of Justice lodged a proposed consent decree with the United States District Court for the Eastern District of Michigan in the lawsuit entitled *United States v. Guardian Industries Corp.*, Civil Action No. 2:15-cv-13426.

The United States filed this lawsuit under the Clean Air Act. The complaint seeks injunctive relief and civil penalties for violations of the Clean Air Act's Prevention of Significant Deterioration requirements at eight float glass manufacturing furnaces owned and operated by the defendant, Guardian Industries Corp., in Kingsburg, California; DeWitt, Iowa; Carleton, Michigan; Geneva, New York; Floreffe, Pennsylvania; Richburg, South Carolina; and Corsicana, Texas. The consent decree requires the defendant to perform injunctive relief, which includes complying with emission limitations that are comprised of numerical or work practice standards that together apply continuously at all times. The defendant will also pay a \$312,000 civil penalty and perform a \$150,000 wood burning appliance replacement mitigation project in the San Joaquin Valley area in California.

The publication of this notice opens a period for public comment on the proposed consent decree. Comments should be addressed to the Assistant Attorney General, Environment and Natural Resources Division, and should refer to *United States v. Guardian Industries Corp.*, D.J. Ref. No. 90-5-2-1-11128. All comments must be submitted no later than thirty (30) days after the publication date of this notice. Comments may be submitted either by email or by mail:

<i>To submit comments:</i>	<i>Send them to:</i>
By email	<i>pubcomment-ees.enrd@usdoj.gov.</i>

<i>To submit comments:</i>	<i>Send them to:</i>
By mail	Assistant Attorney General, U.S. DOJ—ENRD, P.O. Box 7611, Washington, D.C. 20044-7611.

During the public comment period, the proposed consent decree may be examined and downloaded at this Justice Department Web site: <http://www.justice.gov/enrd/consent-decrees>. We will provide a paper copy of the proposed consent decree upon written request and payment of reproduction costs. Please mail your request and payment to:

Consent Decree Library, U.S. DOJ—ENRD, P.O. Box 7611, Washington, DC 20044-7611.

Please enclose a check or money order for \$24.25 (25 cents per page reproduction cost) payable to the United States Treasury. For a paper copy without the exhibits and signature pages, the cost is \$19.50.

Maureen M. Katz,

Assistant Section Chief, Environmental Enforcement Section, Environment and Natural Resources Division.

[FR Doc. 2015-25339 Filed 10-5-15; 8:45 am]

BILLING CODE 4410-15-P

DEPARTMENT OF LABOR

Employee Benefits Security Administration

179th Meeting of the Advisory Council on Employee Welfare and Pension Benefit Plans; Notice of Meeting

Pursuant to the authority contained in Section 512 of the Employee Retirement Income Security Act of 1974 (ERISA), 29 U.S.C. 1142, the 179th open meeting of the Advisory Council on Employee Welfare and Pension Benefit Plans (also known as the ERISA Advisory Council) will be held on November 3-4, 2015.

The meeting will take place in C5320 Room 6, U.S. Department of Labor, 200 Constitution Avenue NW., Washington, DC 20210 on November 3, from 1 p.m. to approximately 5:00 p.m. On